{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:24Z","timestamp":1787027904492,"version":"build-2736575974"},"reference-count":32,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Amgen, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>This study characterizes real-world treatment patterns and economic and healthcare resource utilization (HCRU) burden associated with first-line (1L) treatment of metastatic non-small cell lung cancer (NSCLC) without actionable alterations in the United States. This retrospective observational study used Optum Clinformatics\u00ae data. A total of 15,659 patients with metastatic NSCLC who started 1L treatment between January 2020 and March 2023 were included (52% male; mean age at the start of 1L treatment 71.7 years; 86% Medicare Advantage). The most frequent 1L regimens were immune checkpoint inhibitor (ICI) + platinum-based chemotherapy (PBCT) (47%), PBCT only (26%), and ICI only (20%). The median 1L treatment duration was 4.2 months (range 2.7\u20136.5) and was shorter with chemotherapy-only regimens. Outpatient visits accounted for the majority of HCRU (mean 6.6 visits per patient per month [PPPM]). Outpatient, inpatient, and emergency department visits were highest for chemotherapy-only regimens. Mean total (all-cause) healthcare costs were $32,215 PPPM and were highest for ICI + chemotherapy ($34,741\u201338,454 PPPM). Inpatient costs PPPM were highest for PBCT ($4725) and ICI + non-PBCT ($4648). First-line treatment of metastatic NSCLC without actionable alterations imposes a notable HCRU and cost burden, underscoring the need for better treatment options to improve outcomes and reduce economic impact.<\/jats:p>","DOI":"10.3390\/curroncol32030151","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:56:52Z","timestamp":1741161412000},"page":"151","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US"],"prefix":"10.3390","volume":"32","author":[{"given":"Divyan","family":"Chopra","sequence":"first","affiliation":[{"name":"Amgen, Thousand Oaks, CA 91320, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Waterhouse","sequence":"additional","affiliation":[{"name":"OHC (Oncology Hematology Care), Cincinnati, OH 45242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihtisham","family":"Sultan","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, CA 91320, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3189-409X","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Stollenwerk","sequence":"additional","affiliation":[{"name":"Amgen (EUROPE) GmbH, 6343 Rotkreuz, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"American Cancer Society (2024, June 06). Key Statistics for Lung Cancer. Available online: https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13696998.2024.2437324","article-title":"The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: A cross sectional study in France and Germany","volume":"28","author":"Chouaid","year":"2025","journal-title":"J. Med. Econ."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-023-01436-2","article-title":"Emerging evidence and treatment paradigm of non-small cell lung cancer","volume":"16","author":"Liu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Friedlaender, A., Perol, M., Banna, G.L., Parikh, K., and Addeo, A. (2024). Oncogenic alterations in advanced NSCLC: A molecular super-highway. Biomark Res., 12.","DOI":"10.1186\/s40364-024-00566-0"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/OP.23.00669","article-title":"Molecular Testing in Non-Small-Cell Lung Cancer: A Call to Action","volume":"20","author":"Sathiyapalan","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS (G12C) mutation: A randomised, open-label, phase 3 trial","volume":"401","author":"Johnson","year":"2023","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107921","DOI":"10.1016\/j.lungcan.2024.107921","article-title":"Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation","volume":"196","author":"Waterhouse","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"Lmt36","DOI":"10.2217\/lmt-2020-0003","article-title":"Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver","volume":"9","author":"Kim","year":"2020","journal-title":"Lung Cancer Manag."},{"key":"ref_13","unstructured":"NCCN (2024). NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer Version 11.2024\u201415 October 2024, NCCN."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/07357907.2020.1827415","article-title":"Real-world outcomes and value of first-line therapy for metastatic non-small cell lung cancer","volume":"38","author":"Chastek","year":"2020","journal-title":"Cancer Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1016\/j.cllc.2018.05.016","article-title":"Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated with Second-Line Therapies for Medicare Patients with Advanced Non-Small-Cell Lung Cancer","volume":"19","author":"Arunachalam","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.cllc.2018.02.002","article-title":"Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting","volume":"19","author":"Nadler","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Williams, C.D., Allo, M.A., Gu, L., Vashistha, V., Press, A., and Kelley, M. (2023). Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0282020"},{"key":"ref_19","first-page":"255","article-title":"Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States","volume":"28","author":"Zhang","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.jval.2023.03.571","article-title":"EE270 The Economic Burden of Metastatic Non-Small Cell Lung Cancer in US Patients without an EGFR or ALK Mutation","volume":"26","author":"Simmons","year":"2023","journal-title":"Value Health"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s41669-023-00407-0","article-title":"Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis","volume":"7","author":"Vanderpoel","year":"2023","journal-title":"PharmacoEcon. Open"},{"key":"ref_22","first-page":"S16","article-title":"Real-world treatment patterns, health care costs and health care utilization in US patients with non\u2013small cell lung cancer receiving sotorasib","volume":"29","author":"Chopra","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Meng, W., Ou, W., Chandwani, S., Chen, X., Black, W., and Cai, Z. (2019). Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer. J. Biomed. Inform., 100.","DOI":"10.1016\/j.jbi.2019.103335"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients","volume":"17","author":"Klabunde","year":"2007","journal-title":"Ann. Epidemiol."},{"key":"ref_25","unstructured":"US Bureau of Labor Statistics (2023). CPI for All Urban Consumers (CPI-U), Medical Care in U.S. City Average, All Urban Consumers, Not Seasonally Adjusted."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.37765\/ajmc.2023.89360","article-title":"Better together? costs of first-line chemoimmunotherapy for advanced non-small cell lung cancer","volume":"29","author":"Kish","year":"2023","journal-title":"Am. J. Manag. Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jval.2023.03.349","article-title":"Costs of first-line systemic therapy (1LT) for locally advanced or metastatic non-small cell lung cancer (a\/mNSCLC)\u2014A secondary analysis of claims data from the United States (US) (abstract)","volume":"26","author":"Spira","year":"2023","journal-title":"Value Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100769","DOI":"10.1016\/j.ctarc.2023.100769","article-title":"Immunotherapy in combination with chemotherapy vs. immunotherapy alone for advanced non-small cell lung cancer and programmed death ligand 1 score < 50","volume":"37","author":"Pham","year":"2023","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gines Rubio, J., Delgado, O., Callejo, A., Dominguez, M., and Torres, C. (2024). Healthcare Resource Utilization and Associated Costs among Patients with Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy or Immunotherapy in Spain: A Single-Center, Real-World, Exploratory Study. Cancers, 16.","DOI":"10.3390\/cancers16112068"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Turner, R.M., Chen, Y.W., and Fernandes, A.W. (2017). Validation of a Case-Finding Algorithm for Identifying Patients with Non-small Cell Lung Cancer (NSCLC) in Administrative Claims Databases. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00883"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/151\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:37Z","timestamp":1760028457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["curroncol32030151"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32030151","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]}}}